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BACKGROUND AND PURPOSE
Endocannabinoids alter permeability at various epithelial barriers, and cannabinoid receptors and endocannabinoid levels are
elevated by stroke, with potential neuroprotective effects. We therefore explored the role of endocannabinoids in modulating
blood–brain barrier (BBB) permeability in normal conditions and in an ischaemia/reperfusion model.
EXPERIMENTAL APPROACH
Human brain microvascular endothelial cell and astrocyte co-cultures modelled the BBB. Ischaemia was modelled by
oxygen-glucose deprivation (OGD) and permeability was measured by transepithelial electrical resistance. Endocannabinoids
or endocannabinoid-like compounds were assessed for their ability to modulate baseline permeability or OGD-induced
hyperpermeability. Target sites of action were investigated using receptor antagonists and subsequently identified with
real-time PCR.
KEY RESULTS
Anandamide (10 μM) and oleoylethanolamide (OEA, 10 μM) decreased BBB permeability (i.e. increased resistance). This was
mediated by cannabinoid CB2 receptors, transient receptor potential vanilloid 1 (TRPV1) channels, calcitonin gene-regulated
peptide (CGRP) receptor (anandamide only) and PPARα (OEA only). Application of OEA, palmitoylethanolamide (both PPARα
mediated) or virodhamine (all 10 μM) decreased the OGD-induced increase in permeability during reperfusion.
2-Arachidonoyl glycerol, noladin ether and oleamide did not affect BBB permeability in normal or OGD conditions.
N-arachidonoyl-dopamine increased permeability through a cytotoxic mechanism. PPARα and γ, CB1 receptors, TRPV1
channels and CGRP receptors were expressed in both cell types, but mRNA for CB2 receptors was only present in astrocytes.
CONCLUSION AND IMPLICATION
The endocannabinoids may play an important modulatory role in normal BBB physiology, and also afford protection to the
BBB during ischaemic stroke, through a number of target sites.
Abbreviations
2-AG, 2-arachidonoylglycerol; AEA, anandamide; BBB, blood–brain barrier; CB1, cannabinoid receptor 1; CB2,
cannabinoid receptor 2; CGRP, calcitonin gene-related peptide; ECS, endocannabinoid system; FAAH, fatty acid amide
hydrolase; LDH, lactate dehydrogenase; NADA, N-arachidonoyl-dopamine; OEA, N-oleoylethanolamide; OGD,
oxygen-glucose deprivation; PEA, N-palmitoylethanolamide; RT-PCR, real-time PCR; TEER, transepithelial electrical
resistance; TRPV1, transient receptor potential vanilloid 1
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Introduction
The blood–brain barrier (BBB) is formed by brain endothelial
cells that line the cerebral microvasculature, capillary base-
ment membranes and astrocyte end feet, which surround
99% of the BBB endothelia and play an important role in
maintaining BBB integrity. Tight junctions restrict the para-
cellular pathway for diffusion of hydrophilic solutes, allow-
ing the body to control which substances can gain access to
the brain (Abbott, 2002). Cerebral reperfusion following
ischaemia initiates a cascade of events such as inflammation,
protease activation and oxidative and nitrosative stress,
which increases the permeability of the BBB (Lo et al., 2003).
The compromised state of the BBB aggravates haemorrhagic
transformation and vasogenic oedema, which has profound
neurological consequences (Latour et al., 2004). Indeed,
uncontrolled cerebral oedema represents the leading cause of
patient mortality within the first week following an ischae-
mic stroke (Hacke et al., 1996).
The endocannabinoid system (ECS) is comprised of can-
nabinoid receptors (CB1 and CB2), endogenous lipid ligands
(the endocannabinoids) and enzymes that synthesize and
degrade these compounds (Pertwee et al., 2010). Anandamide
(AEA) and 2-arachidonoylglycerol (2-AG) are the best
studied endocannabinoids, but other, chemically similar,
compounds have been suggested as endocannabinoids
or endogenous cannabinoid-like compounds, including
N-arachidonoyl-dopamine (NADA), noladin ether, oleamide,
N-oleoylethanolamide (OEA), N-palmitoylethanolamide
(PEA) and virodhamine. CB1 and CB2 receptors are not the
only pharmacological targets for cannabinoids, which also
display activity at transient receptor potential vanilloid 1
(TRPV1) channels, GPR55, PPARα and PPARγ (Pertwee et al.,
2010).
Some endocannabinoids have been shown to play a role
in the regulation of BBB permeability in conditions other
than ischaemia. Using in vivo and in vitro models, increased
BBB permeability following chronic head injury and multiple
sclerosis were decreased by the exogenous addition of 2-AG
(Panikashvili et al., 2006) or AEA (Mestre et al., 2011) respec-
tively. Oleamide has been found to inhibit gap junction cou-
pling, thus increasing barrier permeability in vitro using pig
brain microvascular endothelial cells (Nagasawa et al., 2006).
Interestingly, the effect of any other endocannabinoid or
endocannabinoid-like ligand on BBB permeability in normal
conditions has not been investigated.
Components of the ECS are known to be altered by stroke.
Human and animal in vivo data have shown increases in
neurological levels of AEA (peripheral levels also elevated),
2-AG, OEA and PEA (Hillard, 2008; Naccarato et al., 2010).
The expression of cannabinoid receptors is up-regulated in
the rat brain following cerebral ischaemia, indicating that the
ECS may play an important role in the endogenous response
to stroke (see Hillard, 2008). Indeed, exogenous administra-
tion of 2-AG (Wang et al., 2009), AEA (Wang et al., 2009), OEA
(Sun et al., 2007; Zhou et al., 2012) and PEA (Ahmad et al.,
2012b) offer neuroprotection against ischaemic stroke using
in vitro and in vivo models, but the impact on BBB permeabil-
ity in stroke has only been assessed for OEA, where it was
found to decrease in vivo BBB permeability via PPARα (Zhou
et al., 2012).
Because endocannabinoids offer neuroprotection from
stroke and alter BBB permeability in various neurological
disorders, we hypothesized that endocannabinoids might
regulate in vitro BBB permeability in normal and ischaemic
conditions. Our results show for the first time that AEA
and OEA decrease permeability in normal conditions.
When given before oxygen-glucose deprivation (OGD), only
OEA, PEA and virodhamine decreased BBB permeability.
This study illustrates the important role the ECS plays
in regulating BBB permeability via several target sites of
action.
Tables of Links
TARGETS
GPCRsa
CB1 receptors
CB2 receptors
CGRP receptor
Ion channelsb
TRPV1 channels
Nuclear hormone receptorsc
PPARα (NR1C1)
PPARγ (NR1C3)
LIGANDS
2-AG,
2-arachidonoylglycerol
HU308
AEA, anandamide NADA, N-arachidonoyl-dopamine
AM251 Noladin ether, 2-arachidonyl
glyceryl ether
AM630 OEA, N-oleoylethanolamide
Capsazepine Oleamide
CGRP8–37 PEA, N-palmitoylethanolamide
Dexamethasone URB597
GW6471 Virodhamine, O-arachidonoyl
ethanolamine
GW9662
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://
www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are
permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (a,b,cAlexander et al., 2013a,b,c).
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Methods
In vitro BBB co-culture model
Human brain microvascular endothelial cells isolated from
human brain tissue (HBMECs; Catalog #1000, ScienCell,
Carlsbad, CA, USA) and human astrocytes isolated from
human cerebral cortex (HAs; Catalog #1800, ScienCell) were
co-cultured in endothelial cell medium (Catalog #1001; con-
centrations, mL–1; 10 μg apo-transferrin, 10 μg BSA, 2 ng
fibroblast growth factor (FGF)-2, 1 μg hydrocortisone, 2 ng
insulin-like growth factor 1 (IGF-I), 7.5 μg insulin and 20 nM
progesterone, 2% FBS, 5.55 mM glucose and 10 000
units·mL−1 of penicillin and streptomycin) and astrocyte
medium (Catalog #1801; concentrations, mL–1; 10 μg apo-
transferrin, 10 μg BSA, 10 ng EGF, 10 ng FGF-2, 1 μg hydro-
cortisone, 5 μg insulin, 2 ng IGF-I, 0.5 ng IGF LR3 10-8 M
retinoic acid and 2 ng VEGF, 5% FBS, glucose 5.55 mM and
10 000 units·mL−1 of penicillin and streptomycin; both Sci-
enCell). HAs were seeded on the outside of collagen-coated
0.4 μm pore PTFE membrane transwell inserts (12-well type;
Corning Costar, Tewksbury, MA, USA) directed upside down
and allowed to adhere to the membrane overnight. HBMECs
were seeded on the inside of the insert and cells were grown
to confluence to create a contact co-culture model (Allen and
Bayraktutan, 2009; Mestre et al., 2011).
Measurement of BBB permeability
Transepithelial electrical resistance (TEER) was measured as a
marker of co-culture integrity and as a measure of paracellular
permeability. The resistance across the membrane was meas-
ured using STX2 electrodes linked to an EVOM2 resistance
meter (World Precision Instruments, Hitchin, Hertfordshire,
UK). Three readings were taken per insert and the average
value was used. A baseline TEER reading was taken (i.e. 0 h)
and the percentage change from this value was calculated for
subsequent readings. The average TEER was 30.23 ±
0.24 Ω·cm−2, similar to that previously reported using the
same methodology (Allen and Bayraktutan, 2009).
To assess their impact on permeability, endocannabinoids
were added to the luminal (endothelial) chamber and TEER
was measured at various time points over 48 h, at which point
the media was changed, endocannabinoids were reapplied
and TEER was measured for another 48 h. Endocannabinoids
that significantly altered permeability had their mechanism of
action probed using relevant receptor antagonists which were
co-administered with the endocannabinoids.
Real-time PCR (RT-PCR)
Presence of predicted sites of action was investigated at the
mRNA level using reverse transcription followed by PCR (RT-
PCR). Total RNA was extracted from HA and HBMEC cells
using Allprep DNA/RNA kit with on column DNaseI treatment
(Qiagen, Hilden, Germany). Reverse transcription with and
without reverse transcriptase was performed in 20 μL final
volume using 2 μg of total RNA and random primers with the
high capacity cDNA reverse transcription kit (Life Technolo-
gies, Paisley, UK) according to the manufacturer’s instructions.
PCR reactions were carried out in a final volume of 25 μL with
Zymotaq (ZymoResearch, Irvine, CA, USA) using 2 μL of
reverse transcription product as template. Primer pairs used to
amplify PPARα and PPARγ fragments (99bp and 87bp, respec-
tively) were as described in Reynders et al. (2006); those for
128bp hypoxanthine-guanine phosphotibosyl transferase
(HPRT) were from Spinsanti et al. (2008); those for 303 bp CB1
receptor and 365 bp CB2 receptor were from Cencioni et al.
(2010); those for 511 bp TRPV1 were from Luo et al. (2008);
and finally the 380 bp CGRP receptor cDNA fragment was
amplified using the primers reported in Dong et al. (1999).
After 5 min at 95°C, PCRs were performed for 40 cycles except
those for CGRP receptors and CB2 receptors which were carried
out for 60 cycles. The cycles included 30 s at 95°C, 30 s at the
annealing temperature optimal for each primer pair (56°C for
CB1 and CB2 receptors; 60°C for PPARα, PPARγ and HPRT; 58°C
for TRPV1 channel; 61°C for CGRP receptor) and a final
extension step of 30 s at 72°C. Amplification products were
separated by gel electrophoresis through ethidium bromide
stained 2% agarose (CB1 receptor, CB2 receptor, TRPV1
channel, CGRP receptor and HPRT) or 3% metaphore (PPARα
and PPARγ) gels and visualized using a Biorad Chemidoc (Life
Science, Hemel Hampstead, UK).
OGD
Ischaemic conditions were simulated using an OGD protocol.
Cell culture media were replaced with glucose-free RPMI
medium (Invitrogen, Life Technologies) and the plates were
placed into a GasPak EZ Anaerobe Pouch (Beckton Dickinson,
Oxford, UK) with anaerobic conditions being achieved within
20 min, and the inserts were left in OGD conditions for a
further 4 h in the incubator. No preconditioning was carried
out on the cells. After OGD, TEER was read and the RPMI
medium was replaced with the cells’ normal medium and
returned to the incubator. The permeability of the BBB was
assessed throughout the reperfusion period. Medium samples
were collected and stored at −80°C whenever the medium was
changed. Endocannabinoids were added before the OGD pro-
tocol to mimic an endogenous response to ischaemia.
Lactate dehydrogenase (LDH) assay
LDH levels were measured using a commercially available
kit according to the manufacturer’s instructions (LDH-
cytotoxicity assay kit II, Biovision, Milpitas, CA, USA).
Medium samples were transferred into an optically clear
96-well plate and reaction mix (containing water soluble
tetrazolium-1) was added to each well. After 30 min, absorb-
ance was measured at 450 nm, subtracting the 650 nm
reading to correct for optical imperfections in the plate.
Data analysis
Results are presented as means ± SEM. Data were analysed
with GraphPad Prism software (La Jolla, CA, USA), using
either Student’s t-test or one-way ANOVA with Dunnett’s or
Bonferroni’s post hoc test. AUC values were calculated using
the trapezoidal method. In experiments conducted in control
conditions, the baseline was set to be at the lowest value in
the data sets and the area above baseline was calculated. In
the OGD experiments, the baseline was set to be highest
value obtained in the data sets and the area below baseline
was calculated. P < 0.05 was considered significant.
Materials
All endocannabinoids were purchased from Tocris (Bristol,
UK) and dissolved in ethanol to a stock concentration of
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10 mM, except 2-AG which was purchased from Abcam
(Cambridge, UK) and dissolved in acetonitrile. AM251,
AM630, GW6471, GW9662 (all 100 nM), capsazepine,
O-1918 (both 1 μM) (all dissolved in dimethyl sulfoxide) and
CGRP8–37 (2 μM, dissolved in distilled water) were all pur-
chased from Tocris and URB597 (1 μM, dissolved in dimethyl
sulfoxide) was purchased from Sigma (Dorset, UK). All were
dissolved to a stock solution of 10 mM.
Results
Effects of anandamide on BBB permeability
AEA is a well-characterized and frequently studied endocan-
nabinoid displaying effects on epithelial barrier permeability
in BBB and non-BBB sites, therefore, this was the first com-
pound investigated. AEA at 10 μM, but not 100 nM or 1 μM,
decreased permeability (i.e. increased TEER/monolayer resist-
ance) (see Figure 1A,B). In all subsequent antagonist studies,
AEA (10 μM) also significantly increased TEER compared with
vehicle in the same experimental set up as the antagonists.
In these studies, the effect of AEA on BBB permeability was
not inhibited by AM251 (CB1), GW6471 (PPARα), GW9662
(PPARγ) or O1918 (novel endothelial receptor) (see Table 1 for
AUC values). However, the effect of AEA (10 μM) was inhib-
ited by the CB2 antagonist AM630, the TRPV1 antagonist
capsazepine and the CGRP receptor antagonist CGRP8–37
(Figure 1C–E). The synthetic CB2 agonist HU308 and the
steroid dexamethasone (as a positive control) were also able
to significantly increase TEER in this BBB model (Figure 1F,G).
RT-PCR was carried out to profile the expression at the
RNA level of these potential target sites of action in HAs and
HBMECs. PPARs (α and γ), CB1 receptors, TRPV1 channels and
CGRP receptors were found to be present in both cell types.
By contrast, mRNA for CB2 receptors was only present in the
astrocytes (Figure 2).
Inhibition of the degradation of AEA by the fatty acid
amide hydrolase (FAAH) inhibitor URB597 blocked the effects
of AEA such that the change in TEER was no longer signifi-
cantly different to that observed in the vehicle control inserts
(Figure 3).
Exposing the BBB to 4 h OGD increased permeability as
shown by a reduction in TEER of approximately 35%
(Figure 4). AEA did not alter the BBB permeability response to
OGD when applied before (Figure 4A and B) or after the OGD
protocol (Figure 4C and D).
Effects of other endocannabinoids and
endocannabinoid-like compounds on BBB
permeability given in normal conditions
2-AG, noladin ether, oleamide, PEA and virodhamine did
not alter BBB permeability when given in normal conditions
(see Table 1). However, OEA significantly increased TEER
(decreased permeability) in normal conditions at 10 μM (P <
0.01, Figure 5A). A concentration-response curve showed that
a significant response to OEA was only observed at 10 μM
(Figure 5B). The effects of OEA (10 μM) were not inhibited by
AM251, AM630, capsazepine or GW9662 (see Table 1), but
were inhibited by GW6471, a PPARα agonist (P < 0.05,
Figure 5C and D).
After 48 h exposure to a single application of NADA
(10 μM), BBB permeability was significantly increased
(Figure 5E). Following a second application of NADA, BBB
permeability remained significantly below that of vehicle for
another 24 h (see Figure 5E). Visual inspection using a light
microscope showed apparent cellular damage, therefore
levels of LDH in the luminal (endothelial) medium from
NADA-treated inserts were measured and were found to be
significantly greater than vehicle at 48 h (P < 0.001,
Figure 5F).
Effects of endocannabinoids and
endocannabinoid-like compounds on BBB
permeability given before OGD
OEA (P < 0.01, Figure 6A and B), PEA (P < 0.05, Figure 6C and
D) and virodhamine (P < 0.01, Figure 6E and F) given before
OGD all significantly reduced the increase in permeability
induced by the OGD protocol (see AUC values Figure 6B, D
and F). The effects of these compounds were mainly observed
in the reperfusion period rather than the initial increase in
permeability (see Figure 6A, C and E). However, 2-AG, oleam-
ide, NADA and noladin ether had no effect on the permeabil-
ity response to OGD (Figure 6G–J). In a separate experiments,
the protective effect of OEA and PEA given before OGD were
inhibited by the PPARα antagonist GW6471 (Figure 7).
Discussion
The aim of this study was to investigate the potential roles
that endocannabinoids play in the regulation of in vitro BBB
permeability. Our results show that AEA (via TRPV1 channels,
CB2 and CGRP receptors) and OEA (via PPARα) decreased
permeability in normal conditions, while NADA increased
permeability. When given before OGD, OEA, PEA (via PPARα)
and virodhamine decreased BBB permeability. Overall, this
study illustrates the important role the ECS plays in regulat-
ing BBB permeability, identifying a number of potential
targets for future therapies.
Effects of AEA on BBB permeability
We found that AEA decreased BBB permeability (i.e. increases
BBB resistance). This effect of AEA was observed within 2 h of
application, unlike the steroid dexamethasone, where a time-
dependent increase in BBB resistance was observed. AEA has
been shown to reduce BBB permeability using mouse in vivo
and in vitro models, through attenuation of vascular cell
adhesion molecule (VCAM)-1 levels via CB1 receptor activa-
tion (Mestre et al., 2011). In contrast, we found that CB2
receptor activation by AEA was partly responsible for decreas-
ing permeability and showed that a synthetic CB2 receptor
agonist (HU308) was capable of inducing a similar acute
increase in BBB resistance. PCR expression profiling revealed
that the location of CB2 receptors is more likely to be on the
astrocytes than endothelial cells. Activation of CB2 receptors
has also been shown to decrease in vivo BBB permeability in
mice following traumatic brain injury (Amenta et al., 2012) or
inflammation (Ramirez et al., 2012), and following stroke,
CB2 receptor agonists decrease infarct volume by reducing
inflammatory infiltrate (Hillard, 2008). Therefore, activity at
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the BBB could account for some of the protective effects that
CB2 receptor agonists have displayed in animal stroke models.
It is worth noting that the lack of CB2 receptors in the human
brain microvascular endothelial cells isolated from human
brain tissue in the present study is in contrast to previous
studies. This may be related to the source of human tissue. For
example, in the work of Golech et al. (2004), the endothelial
cells were isolated from brains of patients with idiopathic
Figure 1
The effects of increasing concentrations of AEA on BBB permeability measured by TEER (A) with corresponding AUC (B) (n = 9 inserts from three
separate experiments). The effects of capsazepine (Cpz) (C) (n = 7 inserts from three separate experiments) or AM630 (D) (n = 7–8 inserts from
three separate experiments) or CGRP (E) (n = 5–6 inserts from three separate experiments) on the effect of AEA (10 μM). The effects of
dexamethasone (n = 6) and the CB2 agonist HU308 on BBB permeability over time (F) and expressed as AUC (G). Data are given as mean ± SEM.
***P < 0.001, **P < 0.01, *P < 0.05; AEA compared with vehicle-treated inserts; ††P < 0.01; AEA and antagonist compared with AEA alone;
#P < 0.05, ##P < 0.01; HU308 compared with vehicle; one-way ANOVA with Dunnett’s (B) or Bonferroni’s test (C,D,E).
BJPEndocannabinoids modulate BBB permeability
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epilepsy. In the endothelium of human glioblastomas, CB2
receptors are expressed in about half of the cells (Schley et al.,
2009). In multiple sclerosis, CB2 receptors have also been
identified on the endothelium of cerebral arteries (Zhang
et al., 2011). As CB2 receptors are known to be up-regulated in
pathologies and in response to inflammation and stress, this
may explain the expression of CB2 receptors in these studies
and not in the cells in the present study, which are derived
from normal tissue. In support of this, Ramirez et al. (2012)
showed little CB2 receptor immunoreactivity in healthy brain
endothelium or on human brain microvascular endothelial
cells, but CB2 receptors were highly up-regulated in patients
with encephalitis or after an inflammatory insult and were
capable of reducing BBB permeability in these situations.
A recent study from our group showed that AEA activa-
tion of TRPV1 channels on the basolateral side of Caco-2 cells
(human epithelial colorectal adenocarcinoma cells) reduced
permeability, potentially via increases in tight junction pro-
teins (Alhamoruni et al., 2010), and the present study further
demonstrates the permeability reducing properties of
TRPV1 channel activation at epithelial barriers. Activation of
TRPV1 channels by AEA is known to increase CGRP release
(Zygmunt et al., 1999); therefore, AEA may mediate its effects
via increased CGRP levels, as suggested by the effect of the
CGRP receptor antagonist in the present study. Both TRPV1
channel and CGRP receptor mRNA were demonstrated in
brain endothelial cells and in astrocytes. This is consistent
with a recent study showing that CGRP activation decreased
cerebral oedema and BBB permeability following ischaemic
stroke in the rat (Liu et al., 2011).
Inhibiting the degradation of AEA using the FAAH inhibi-
tor URB597 also inhibited the effects of AEA, which suggests
that metabolic products of AEA degradation are also involved
in the effects of AEA effect on BBB permeability. This may
seem contradictory to our data showing the effects of AEA
through activation of CB2 receptors and TRPV1 channels,
although this may not be the case. It has been shown for
example that a cytochrome P450-derived epoxygenated
metabolite of AEA, 5,6-epoxyeicosatrienoic acid ethanola-
mide, is a selective CB2 receptor agonist (Snider et al., 2009)
and epoxyeicosatrienoic acids derived from AEA can activate
TRPV4 channels (Watanabe et al., 2003), so the possibility
exists that in our model, it is the metabolites of AEA that
modulate BBB permeability through CB2 receptors and TRPV1
channesl.
Although AEA reduced BBB permeability in normal con-
ditions, it had no effect when given either before or after
OGD. The increase in permeability caused by OGD was
greater than the increase in TEER induced by AEA, suggesting
the effect of AEA is not strong enough to alter permeability
overall. Alternatively, the expression or function of the
targets involved, CB2 receptors and TRPV1 channels, might
be altered by the OGD protocol. Perhaps, a negative effect of
AEA on BBB permeability through activation of CB1 receptors
is revealed in ischaemic conditions (Alhamoruni et al., 2012).
Either way, protecting BBB permeability in ischaemia does
not appear to underlie the neuroprotective effects of AEA
observed in stroke.
Effects of other endocannabinoids and
endocannabinoid-like compounds on
BBB permeability
Like AEA, we found that OEA decreased permeability
(increased TEER) when given in normal conditions or in the
presence of OGD and both of these responses were via PPARα
activation. PPARα mRNA was confirmed in both the endothe-
lial cells and astrocytes. These data in human cells are con-
sistent with in vivo mouse studies where OEA reduced infarct
volume, oedema and BBB disruption following ischaemic
stroke through activation of PPARα (Sun et al., 2007; Zhou
et al., 2012). Fenofibrate, a synthetic PPARα agonist, also pro-
tected a rodent in vitro BBB model from hyperpermeability
following OGD (Mysiorek et al., 2009). PPARα agonists
inhibit expression of the adhesion molecules, VCAM-1 and
ICAM-1, down-regulate MMPs and protease activity and
up-regulate tight junction proteins (Marx et al., 1999;
Deplanque et al., 2003; Huang et al., 2009), all of which are
beneficial to BBB integrity. OEA is produced by neurons and
glial cells following ischaemia (Hillard, 2008). Hence, OEA
activity at PPARα could form an important component of the
body’s innate defence following stroke, with data from the
present study suggesting actions at the BBB may be crucial to
this beneficial effect of OEA.
Table 1
AUC values for the effects of cannabinoids on TEER
TEER (AUC)
Vehicle
Endocannabinoid
(10 μM)
AEA 3027 ± 328 4315 ± 303*
+AM251 2355 ± 205 3380 ± 210†
+GW6471 2841 ± 129 3595 ± 99††
+GW9662 2626 ± 148 3362 ± 145†
+O-1918 2369 ± 60 3359 ± 240††
OEA 1649 ± 124 2646 ± 133***
+AM251 1356 ± 171 2205 ± 208††
+AM630 1333 ± 164 2040 ± 50††
+Capsazepine 1274 ± 262 2060 ± 57†
+GW9662 1391 ± 182 2008 ± 129†
2-AG 2572 ± 104 2854 ± 351
NADA 2699 ± 104 2060 ± 204*
Noladin ether 2342 ± 208 2718 ± 192
Oleamide 2320 ± 205 2399 ± 176
PEA 2004 ± 104 2349 ± 350
Virodhamine 1850 ± 104 2183 ± 179
All data are from experiments conducted in normal conditions
(i.e. no OGD). Data are given as mean ± SEM. ***P < 0.001, *P
< 0.05 compared with vehicle-treated inserts; ††P < 0.01, †P <
0.05 endocannabinoid and antagonist compared with endocan-
nabinoid alone; Student’s t-test or one-way ANOVA with Bonfer-
roni’s test (antagonist experiments). AM251, CB1 antagonist;
capsazepine, TRPV1 antagonist; GW6471, PPARα antagonist;
GW9662, PPARγ antagonist; O1918, novel endothelial receptor
antagonist.
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Figure 2
Expression profiling of potential target sites of action in HA and HBMEC cells. Shown are the ethidium bromide-stained gels of the products
obtained by RT-PCR using primers specific for PPARα, PPARγ, CB1 receptors, CB2 receptors, TRPV1 channels, CGRP receptors and the control gene
HPRT. cDNAs generated in the presence (+) or absence (−) of reverse transcriptase on total RNA from HA or HBMEC cells were used as template
for the PCRs. The 100 bp DNA ladder was used in all gels except for PPARα and PPARγ where a 10 bp ladder was used. Sizes are in base pairs.
Figure 3
The effects of AEA (n = 6) in the presence and absence of the FAAH inhibitor URB597 (n = 6) on permeability in the BBB (A), with corresponding
AUC (B). Data are given as mean ± SEM. **P < 0.01, *P < 0.05 AEA versus the vehicle; ††P < 0.01 AEA and antagonist compared with AEA alone;
one-way ANOVA with Dunnett’s test.
BJPEndocannabinoids modulate BBB permeability
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2-AG, noladin ether and oleamide did not affect BBB
permeability. These endocannabinoids are known to activate
receptors that we have shown to modify the permeability of
the BBB in the present study (i.e. CB2 receptors and PPARα),
so it is unclear why their effects are dissimilar to AEA and
OEA. However, endocannabinoids are known to have com-
plicated pharmacology which may be explained by a number
of phenomena including mechanisms of cell transport and
trafficking, metabolism and pharmacologically active meta-
bolites, agonist bias, allosteric modulation and activation of
other target sites that might oppose any effects at CB2 recep-
tors or PPARα (Alexander and Kendall, 2007; Kenakin, 2009;
Console-Bram et al., 2012; Fowler, 2013).
We found that PEA and virodhamine did not alter the
permeability of the BBB in normal conditions, but they did
decrease permeability following OGD. Similar to OEA, the
permeability-lowering effects of PEA were inhibited by the
presence of a PPARα antagonist, further confirming the role
for this receptor in modulating BBB permeability in ischae-
mia. PEA has been shown to reduce oedema and brain infarct
size in mice using models of two separate diseases, both of
which cause BBB damage, traumatic brain injury (Ahmad
Figure 4
The effects of various concentrations of AEA either before (A) (n = 7–12 inserts from four separate experiments) or after (C) (n = 9–10 inserts from
four separate experiments) 4 h OGD on permeability in the BBB, with corresponding AUC (B and D). Data are given as mean ± SEM. # , * (10
μM) † (30 μM), P < 0.05; compared with vehicle; one-way ANOVA with Dunnett’s test.
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Figure 5
The effect of OEA over time on BBB permeability in the initial endocannabinoid screening (A) (n = 6 inserts from three separate experiments) as
a concentration-response curve (B) (n = 4–6 inserts from three separate experiments) and in the presence of the PPARα antagonist GW6471 (C
and D) (n = 5 inserts from three separate experiments). (E) The effects of NADA (10 μM) on TEER values in the BBB model (n = 7–8 inserts from
four separate experiments). (F) Absorbance values for LDH assay conducted on cell culture medium obtained from the luminal (endothelial)
chamber of the inserts at 48 h (n = 6 inserts from three separate experiments). Data are given as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05;
OEA compared to vehicles treated inserts; †††P < 0.001, ††P < 0.01; OEA and antagonist compared with OEA alone; one-way ANOVA with Dunnett’s
or Bonferroni’s test.
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Figure 6
The effect of OEA (A and B) (n = 6 inserts from three separate experiments), PEA (C and D) (n = 5–6 inserts from three separate experiments),
virodhamine (E and F) (n = 6 inserts from three separate experiments), 2-AG (G) (n = 6 inserts from three separate experiments), oleamide (H)
(n = 6 inserts from three separate experiments), NADA (I) (n = 4–5 inserts from two separate experiments) and noladin ether (J) (n = 5 inserts from
three separate experiments) administered before 4 h OGD on TEER. Data are given as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05; compared
with vehicle-treated inserts; Student’s t-test.
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et al., 2012a) and ischaemic stroke (Ahmad et al., 2012b).
Neurological PEA levels in human stroke patients are
increased following ischaemia (Schabitz et al., 2002), which
suggests a protective role for PEA in stroke, with permeability-
reducing effects on the BBB potentially forming part of this.
To date, no studies have investigated the effects of virod-
hamine on epithelial barrier permeability or stroke. However,
virodhamine does inhibit neutrophil migration through CB1
receptor activation (McHugh et al., 2008). Neutrophil accu-
mulation and infiltration into the cerebral microvasculature
plays a critical role in neuronal injury following cerebral
ischaemia, especially during reperfusion (Sughrue et al.,
2004). Attenuation of neutrophil migration may be of benefit
in treating hyperacute stroke, but previous trials assessing
compounds that inhibit neutrophilic function have been
ineffective (Krams et al., 2003).
NADA was found to increase BBB permeability with evi-
dence of cell damage. In support of these findings, NADA
has been shown to cause concentration-dependent
cytotoxicity in human, murine or rat hepatic stellate cells
(Wojtalla et al., 2012) and human peripheral blood mono-
nuclear cells (Saunders et al., 2009). Interestingly, although
NADA increased the permeability of the BBB in normal con-
ditions, it did not further increase the permeability of
inserts that were exposed to 4 h OGD. This is most likely
because of the fact that in this protocol, the cells were
only exposed to NADA for 4 h compared with 96 h in the
non-OGD experiments, and that the cytotoxic effects of
NADA are revealed with longer exposure times. NADA is
known to be produced in bovine and rat brains (Walker
et al., 2002), but no studies have investigated whether
stroke alters the levels of NADA and what consequence this
might have.
Of note, the effects of endocannabinoids were only
observed in the high micromolar concentrations. This may
be partly because of technical issues such as binding of endo-
cannabinoids to cell culture plastic (see Fowler et al., 2004),
interactions with FBS or BSA in culture medium or the trans-
port of endocannabinoids into and across the cell, which is
particularly relevant for the PPARα-activating endocannabi-
noids (Kaczocha et al., 2012). In addition, although studies
have investigated the levels of endocannabinoid in the brain,
it is not known what the exact intracellular concentration of
endocannabinoids is when their synthesis is stimulated.
Despite this, the concentration of endocannabinoids
required in the present study are in line with the known
receptor affinity for AEA at CB2 receptors (Ki up to 2 μM) and
TRPV1 channels (EC50 ranging from 0.63 to 4.9 μM depend-
ing on assay) (Pertwee et al., 2010) and for OEA and PEA at
PPARα (EC50 3–4 μM, O’Sullivan, 2007).
In conclusion, this study demonstrates that AEA, OEA,
PEA and virodhamine (all 10 μM) decrease BBB permeability
in vitro in human cells. Roles for CB2 receptors, TRPV1 chan-
nels, CGRP receptors and PPARα activation are presented,
which, in conjunction with published data, identify them as
potential targets to modulate BBB permeability.
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